To view this email as a web page, click here

A pioneer outsourcing services provider for ocular drug development

---

The 20 years of Iris Pharma in 20 key dates

This specialist CRO is one of the world leaders and among the most respected global drug development service companies in ophthalmology.

---

Testimonials


“Iris Pharma is our preferred partner for preclinical work in ophthalmology. Their stellar study conduct and expert advice have been crucial for advancing our AMD program. The staff at Iris Pharma is highly responsive to the challenges of drug development and excels at providing customized solutions quickly.”
 




“Recently Novagali Pharma has been awarded the 2009 North American Frost & Sullivan Award for Industry Innovation & Advancement of the Year for our two proprietary emulsion technology platforms, Novasorb and Eyeject. We are very proud of this award and our excellent, long-standing and fruitful collaboration with Iris Pharma has certainly played a critical role in this success. Working with Iris Pharma has significantly improved our ability to clarify issues and innovative design. The cutting-edge knowledge in ophthalmology of Iris Pharma staff, along with a forward-thinking state of mind have helped us lead our products intelligently through the preclinical and clinical stages all the way to the market."
 
Jean-Sébastien Garrigue, Director of Research and Development, Novagali Pharma SA, Evry, France




"Promedica International, located in California, initiated its relationship with Iris Pharma almost four years ago.  Since then, our project teams have worked closely to coordinate systems and procedures for start-up and implementation of studies in the US and Europe, and we have collaborated on a variety of clinical research projects involving anterior and posterior segment ophthalmic conditions and therapies. 

Due to the tenure of both companies’ management teams, we have come to know each other quite well.  This facilitates efficient and effective ongoing communication between our organizations.

From PMI’s perspective, key benefits in working together with Iris Pharma are as follows:


We so value our relationship with Iris Pharma, and congratulate them on accomplishment of this important milestone – 20 years of business success!

Ginger Clasby, Executive VP, Business Development, Promedica International, Costa Mesa, CA, USA

---

Iris Pharma and its partners around the world



More information on our partnerships

---

Iris Pharma services

The development process of a drug is long, complex and expensive, and even though some stages are known and well defined, each project is unique and requires specific thinking. There is no straightforward path to the market.

Iris Pharma is specialized in the development of ocular drugs and ophthalmic medical devices. This has allowed us to acquire in over 20 years a unique experience and expertise to assist you in mastering the development process and save time and money. Our service range covers all the preclinical and clinical requirements and whether you are experts or novices in ophthalmology, a young biotech or big pharmaceutical company, we will always provide you the best solution and the best quality of service so that together we can make your product progress.

Our company offers individual services and solutions or as part of an integrated program (one-stop shop solution):


Focus on Iris Pharma strategic consulting services

Strategic consulting at Iris Pharma is a service you can get on demand but it is also something that is provided when the studies are performed in our laboratories.

With about 1,600 preclinical studies and more than 80 clinical studies in ophthalmology performed over the last 20 years for more than 150 clients worldwide and almost 50 drugs marketed tested in our laboratories, Iris Pharma has built an extraordinary knowledge base concerning ocular drug and medical device development that allows us to advise and guide our clients in their drug development strategy and decision making.

Thanks to this unique and extensive experience in ophthalmology, Iris Pharma provides the necessary understanding and expertise to guarantee accurate consulting services at every stage of the drug development process from proof of concept studies to Phase IV clinical trials. As a partner, we help you to make the right decisions to develop successful ocular drugs and devices in a cost-effective and rapid manner.


"Step by step" consulting services
Working with Iris Pharma isn’t simply having highly qualified technicians or ophthalmologists acclaimed in their field perform preclinical or clinical studies. It is also the guarantee of a permanent and quality guidance by a specialist irrespective of the development level of your ophthalmic drug or ocular device.

Our expert team is capable, at each step, of advising you, proposing possible alternatives and guiding you towards the best solution with regard to your needs and objectives. We take the time to think through the results together and examine the following steps.


Strategic and global drug development consulting services
"One-stop shop solution". You have a development project for an ophthalmic drug or ocular device and you wish to have an accurate vision of the different middle and long term steps required to reach human experimentation or to market your drug? We can propose a complete design integrating timelines, regulatory requirements and costs to bring your compound or device to where you may want.


Experts meeting organization
Thanks to a vast international experts, researchers and specialists network, we can bring together for you the best current competences in ophthalmology to help you in the development of your project.

Training
You wish to further your knowledge in ophthalmology, improve your surgical technique (administration, injections, dissections, sampling, etc.), expand your knowledge on a specific subject such as the different methods of ocular drug delivery, how to reach effectively the target tissue, what model(s) to choose as a function of your product? Our experts can provide training on demand so that you can become familiar with the latest advances in ophthalmology.
Given that ophthalmology research advances quickly and things evolve, we can offer you the necessary resources to reinforce your knowledge and remain competitive.


Some of the "pluses" we can offer:


For more information on how we can help you, please contact our team at info@iris-pharma.com

New dry eye model in albino rabbits

The Iris Pharma Research Team has developed a new dry eye model in albino rabbits to add to its catalog of animal models designed for preclinical testing in the field of ophthalmology.

This dry eye model in rabbits is induced by repeated daily instillations of 1.0% atropine sulfate. The model produces rapidly some typical dry eye symptoms such as a significant reduction in tear volume, Tear Break-Up Time (TBUT), corneal staining and histopathological signs of dryness and inflammation, and can be satisfactorily used for a preliminary assessment of the protective activity of some polymeric tear substitutes.

Today dry eye syndrome, or keratoconjunctivitis sicca (KCS), affects tens of millions of people worldwide, representing one of the most common ocular diseases.

Click here for more information on our ocular efficacy models.

• May 1-2, 2009: 12th Annual Vision Research Conference, Mechanisms of Macular Degeneration, Fort Lauderdale, FL, USA.

Olivier Brisse, French 35 years old visually impaired windsurfer, broke two windsurfing world records: pride and hope for the visually impaired!
 

Following the attempts and falls of the previous day, Olivier Brisse broke on Thursday 22 January 2009 two distance and speed windsurfing world records for the visually impaired: a distance measured with a GPS of 1.1 kilometers, on the same side, without falls in the morning and a run measured at 23.6 knots by the GPS, i.e. 43.7 km/h, in the afternoon with serious conditions and a wind blowing at 70 km/h.

Windsurfing with such a wind is difficult for the non-impaired, for the visually impaired it is a remarkable achievement. It is also the demonstration of a category of persons for whom we do not even suspect the capacity to carry out certain actions, which seem impossible for certain “non-handicapped”. Olivier Brisse has waved the flag of courage, hope and dignity in his category.